This article is more than 5 years old. Information may no longer be current.

CARISMA

Cardiac Arrhythmias and Risk Stratification After Myocardial Infarction

Issue: September 2010

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Trial determined whether risk stratification tests could predict serious arrhythmic events after acute MI in patients with reduced LVEF (≤0.40).

Patients: 5,869

Centers: multicenter

Countries: Europe

RESULTS: The strongest predictors of the primary endpoint of electrocardiogram-documented ventricular fibrillation or symptomatic sustained ventricular tachycardia were measures of heart rate variability; for example, HR for reduced very-low frequency component (<5.7 in ms2) adjusted for clinical variables, which was 7.0 (95% CI, 2.4–20.3; P<.001).

Published in Eur Heart J. 2009;30:689-698

Click here to read more about the CARISMA trial.